First Episode Schizophrenia-Spectrum Disorders: What Clinicians Need to Know-Presentation Slides

Presentation Slides

Pdf Summary

This document is a summary of a webinar titled "First Episode Schizophrenia-spectrum Disorders: What Clinicians Need to Know." The webinar was part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative implemented by the American Psychiatric Association (APA) and funded by the Substance Abuse and Mental Health Services Administration (SAMHSA). The webinar aimed to provide clinicians with important information and recommendations regarding the treatment of first episode schizophrenia-spectrum disorders. <br /><br />The webinar discussed various topics such as the major findings from first episode treatment studies, side effects of medication treatment, health risks for individuals with schizophrenia, and guidelines for minimizing these risks. It emphasized the importance of shared decision-making between clinicians and patients, with a focus on choosing the most appropriate antipsychotic medication based on the evidence base and considering patient preferences. <br /><br />The webinar also highlighted the risk factors for non-adherence to medication and the importance of preparing for non-adherence by educating patients and families, monitoring for medication adherence, and considering options such as long-acting formulations of antipsychotics. It emphasized the need for close monitoring of side effects and regular assessment of medical co-morbidities.<br /><br />Overall, the webinar provided valuable information for clinicians treating patients with first episode schizophrenia-spectrum disorders, emphasizing the importance of evidence-based treatment, shared decision-making, and close monitoring of symptoms, side effects, and medical co-morbidities.

Keywords

First Episode Schizophrenia-spectrum Disorders

Clinical Support System for Serious Mental Illness

American Psychiatric Association

Substance Abuse and Mental Health Services Administration

treatment

antipsychotic medication

shared decision-making

medication adherence

risk factors

medical co-morbidities